Patient, Oncologist, and Payer Preferences for Adjuvant Endocrine Therapy and CDK4/6 Inhibitor Regimens in Early-Stage Breast Cancer: A Discrete Choice Experiment.

导出 LinkOut

翻译打印收藏纠错

作者： Kathleen,Beusterien ^[1] ; Martine C,Maculaitis ^[2] ; Bernadette,Hallissey ^[1] ; Michael M,Gaschler ^[2] ; Mary Lou,Smith ^[3] ; Ernest H,Law ^[4]

作者单位： Kantar, Health Division, Horsham, PA, USA. ^[1] Kantar, Health Division, New York, NY, USA. ^[2] Research Advocacy Network, Plano, TX, USA. ^[3] Pfizer Oncology, Pfizer Inc, New York, NY, USA. ^[4]

关键词 cyclin-dependent kinase 4/6 inhibitors endocrine therapy stage II/III breast cancer treatment preferences

DOI 10.2147/PPA.S298670

PMID 33776424

发布时间 2022-04-21

翻译满意度评价：

准确一般字义偏差语意偏离译文作用小提交

浏览2

Patient preference and adherence

2021年15卷

611-623页

相似文献

中文期刊
外文期刊
学位论文
会议论文

检索历史清除

Patient, Oncologist, and Payer Preferences for Adjuvant Endocrine Therapy and CDK4/6 Inhibitor Regimens in Early-Stage Breast Cancer: A Discrete Choice Experiment.

Patient preference and adherence

相似文献

Patient preference and adherence

相关期刊

参考文献：
指定格式：	NoteExpress EndNote RefWorks NoteFirst

检索历史 清除

Patient, Oncologist, and Payer Preferences for Adjuvant Endocrine Therapy and CDK4/6 Inhibitor Regimens in Early-Stage Breast Cancer: A Discrete Choice Experiment.

Patient preference and adherence

相似文献

Patient preference and adherence

相关期刊

检索历史清除